EMAIL THIS PAGE TO A FRIEND

Bioorganic & medicinal chemistry letters

Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.


PMID 22765892

Abstract

A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

W325600
Benzothiazole, ≥96%, FG
C7H5NS
101338
Benzothiazole, 96%
C7H5NS